Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -57.57% | -30.41% | 13.36% | 220.65% | 27.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.60% | -44.87% | -18.07% | 127.10% | 79.57% |
| Operating Income | 70.60% | 44.87% | 18.07% | -127.10% | -79.57% |
| Income Before Tax | 70.88% | 44.81% | 18.12% | -128.27% | -2.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -187.71% | 44.81% | -83.46% | 236.77% | -2.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.43% | 24.84% | -110.25% | 236.77% | -2.88% |
| EBIT | 70.60% | 44.87% | 18.07% | -127.10% | -79.57% |
| EBITDA | 69.71% | 44.79% | 18.77% | -127.21% | -79.82% |
| EPS Basic | 37.57% | 93.64% | 89.78% | 108.56% | 83.45% |
| Normalized Basic EPS | 104.82% | 95.41% | 95.95% | 85.23% | 71.55% |
| EPS Diluted | 37.57% | 93.64% | 89.78% | 101.05% | 83.45% |
| Normalized Diluted EPS | 104.82% | 95.41% | 95.95% | 98.21% | 71.55% |
| Average Basic Shares Outstanding | 339.92% | 1,103.28% | 1,921.32% | 1,445.61% | 533.77% |
| Average Diluted Shares Outstanding | 339.92% | 1,103.28% | 1,921.32% | 12,629.39% | 533.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |